Israel-based, Teva Pharmaceuticals, (NYSE: TEVA) the world’s largest generic drugmaker has partnered with Tel Aviv-based Syqe Medical to market medical cannabis for pain management that is administrated via an inhaler. Teva will market the breakthrough product to the roughly 26,000 patients in Israel who are currently licensed to use medical cannabis, a number that is expected to double in the next couple years, according to data cited by the companies.
In a statement on Monday, the two companies stated that this is the first time the medical cannabis sector has complied with pharmaceutical standards for inhalation, which is the most efficient means for administering the cannabis plant. .
“Teva Israel is entering the field of medical cannabis out of a deep commitment to patients coping with pain, which is one of the company’s core therapeutic areas,” said Teva CEO Avinoam Sapir in an article in The Jerusalem Post.
Until now, pain relief from medical cannabis has been delivered via edibles containing the plant; inhaling smoke; or through commercial inhalers. None of those, however, provide reliable or accurate doses.
Approximately 90% of medical cannabis consumers worldwide take it by inhalation, and the Syqe inhaler allows them to receive the optimal dose for their condition, alleviating suffering in the most efficient possible way, the companies said
Source: The Jerusalem Post
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of PotNetwork.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://potnetwork.com/legal-disclaimer/.